Keywords: AstraZeneca, Abbott, Certriad, Mixed dyslipedemia, Gilead, Ambrisentan, IPF, Pulmonary fibrosis
AstraZeneca ends Certriad development with Abbott; Gilead drops ambrisentan in IPF
Article | 23 December 2010
Anglo-Swedish drug major AstraZeneca (LSE: AZN) last evening notified its partner Abbott Laboratories (NYSE: ABT) that it will discontinue the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
